Alvotech (ALVO) - Total Liabilities
Based on the latest financial reports, Alvotech (ALVO) has total liabilities worth Ikr1.59 Billion ISK (≈ $12.93 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Alvotech long-term investment intensity to see how much of total assets are deployed in long-term investments.
Alvotech - Total Liabilities Trend (2020–2024)
This chart illustrates how Alvotech's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see how large is Alvotech's balance sheet.
Alvotech Competitors by Total Liabilities
The table below lists competitors of Alvotech ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
WEIBO CORP. A
F:2WB
|
Germany | €3.08 Billion |
|
Norbit ASA
OL:NORBT
|
Norway | Nkr1.24 Billion |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030
|
China | CN¥1.07 Billion |
|
Shenzhen Yanmade Technology Inc
SHG:688312
|
China | CN¥231.65 Million |
|
Naruida Technology Co. Ltd. Cl A
SHG:688522
|
China | CN¥341.60 Million |
|
Tompkins Financial Corporation
NYSE MKT:TMP
|
USA | $7.68 Billion |
|
Bombay Burmah Trading Corporation Limited
NSE:BBTC
|
India | Rs60.62 Billion |
|
Jupiter Wagons Limited
NSE:JWL
|
India | Rs17.26 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Alvotech's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See ALVO net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.42 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -8.97 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.13 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Alvotech's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Alvotech (2020–2024)
The table below shows the annual total liabilities of Alvotech from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Ikr1.63 Billion ≈ $13.32 Million |
-13.20% |
| 2023-12-31 | Ikr1.88 Billion ≈ $15.35 Million |
+35.16% |
| 2022-12-31 | Ikr1.39 Billion ≈ $11.36 Million |
+89.87% |
| 2021-12-31 | Ikr733.59 Million ≈ $5.98 Million |
-45.32% |
| 2020-12-31 | Ikr1.34 Billion ≈ $10.94 Million |
-- |
About Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic art… Read more